EP3769781

ASTRAZENECA AB
Application Number
EP20174805A
Filing Date
Aug 18, 2016
Status
Granted And Under Opposition
Mar 17, 2023
Grant Date
Apr 19, 2023
External Links
Slate, Register

Biblio Summary

The patent EP3769781B1 was granted on Apr 19, 2023 by Astrazeneca Ab The patent is currently Granted And Under Opposition.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALD GMBHJan 18, 2024ADMISSIBLE

The table below shows the patents of Astrazeneca Ab that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3045466(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of DiabetesOct 16, 20241
EP4114465Anti-Ifnar1 Dosing Regime For Subcutaneous InjectionAug 30, 20231
EP2508188Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol HydrateMay 10, 20235